Abstract: The present invention provides imidazotriazinone compounds which are inhibitors of phosphodiesterase 9. The present invention further provides processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of PDE9 associated diseases or disorders in mammals, including humans.

Abstract: (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide has been found to have procognitive effects in humans at unexpectedly low doses. Thus, (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof can be used at unexpectedly low doses to improve cognition.

Abstract: A method for assessing the state of Alzheimer's disease in patients is disclosed. A method for monitoring the progression of Alzheimer's disease in patients is also disclosed. The method applies detection of specific peptide markers, e.g., using mass spectrometric analysis.

Abstract: A method for assessing the state of Alzheimer's disease in patients is disclosed. A method for monitoring the progression of Alzheimer's disease in patients is also disclosed. The method applies detection of specific peptide markers, e.g., using mass spectrometric analysis.

Abstract: The present invention provides targeted treatment to subjects suffering from Frontotemporal lobar degeneration through use of FTLD targeted agents, as described in the present invention. In particular, the FTLD targeted agents provided herein demonstrate high brain penetration, which decreases risk issues associated with peripheral administration. Furthermore, the FTLD targeted agents of the present invention, when administered to a subject selected for treatment based on the results of a FTLD diagnostic assay, offer targeted treatment of FTLD.

Abstract: A method for improving or treating a Limited Cognitive Impairment (LCI) comprising administering to a subject a compound of the invention, or a pharmaceutically acceptable salt thereof is described together with related compositions.

Abstract: (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide has been found to have procognitive effects in humans at unexpectedly low doses. Thus, (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof can be used at unexpectedly low doses to improve cognition.

Abstract: A method for improving cognition comprising co-administering to a subject an alpha 7 agonist, or a pharmaceutically acceptable salt thereof and a tobacco-free nicotine dosage is described together with related compositions.

Abstract: (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide has been found to have procognitive effects in humans at unexpectedly low doses. Thus, (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof can be used at unexpectedly low doses to improve cognition.

Abstract: (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide has been found to have procognitive effects in humans at unexpectedly low doses. Thus, (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof can be used at unexpectedly low doses improve cognition.

Abstract: (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide has been found to have procognitive effects in humans at unexpectedly low doses. Thus, (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof can be used at unexpectedly low doses to improve cognition.

Abstract: A method for treating inflammation comprising administering to a patient (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide or a pharmaceutically acceptable salt thereof or (R)-7-(2-methoxyphenyl)-N-(quinuclidin-3-yl)benzofuran-2-carboxamide or certain other alpha 7 receptor agonists combination with an acetylcholinesterase inhibitor.

Abstract: A method for improving cognition comprising administering to a patient certain alpha-7 receptor agonists and an acetylcholinesterase inhibitor is described together with related compositions.

Abstract: The invention relates to a crimping tool (1) having crimp indentors and a through-opening for the introduction of a cable end which is to be crimped, introduction of the cable end being limited by an adjustable stop part (2) which is fixedly connected to the crimping tool (1), but is preferably operationally releasable, furthermore, the stop part (2) having different stop pins (3) which can be selectively activated by being pushed down and, if a different stop pin (3) is selected, the activated stop pin (3), which is biased into its non-activated position, having to be released from the stop position. In order to provide a crimping tool with a stop part for which there is advantageous adjustment from one activated stop pin to another activated stop pin, it is proposed that the activated stop pin (3) is retained by a spring latching means formed by a retaining spring (6), and the spring latching means can be deactivated by a release movement of the stop part (2).

Abstract: (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide has been found to have procognitive effects in humans at unexpectedly low doses. Thus, (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof can be used at unexpectedly low doses improve cognition.

Abstract: A method for improving cognition comprising administering to a patient (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide or a pharmaceutically acceptable salt thereof and an acetylcholinesterase inhibitor is described together with related compositions.

Abstract: The invention relates to a crimping tool (1) having crimp indentors and a through-opening for the introduction of a cable end which is to be crimped, introduction of the cable end being limited by an adjustable stop part (2) which is fixedly connected to the crimping tool (1), but is preferably operationally releasable, furthermore, the stop part (2) having different stop pins (3) which can be selectively activated by being pushed down and, if a different stop pin (3) is selected, the activated stop pin (3), which is biased into its non-activated position, having to be released from the stop position. In order to provide a crimping tool with a stop part for which there is advantageous adjustment from one activated stop pin to another activated stop pin, it is proposed that the activated stop pin (3) is retained by a spring latching means formed by a retaining spring (6), and the spring latching means can be deactivated by a release movement of the stop part (2).

Abstract: A method for operating an internal combustion engine, injects fuel directly into a combustion chamber as a main injection, a postinjection and optionally also as a preinjection. An injection nozzle with a plurality of injection bores effects the preinjection and the postinjection preferably which is carried out cyclically. To minimize wetting of the combustion chamber walls, during the postinjection the partial quantities of fuel and a lift of the nozzle needle of the injection nozzle are set so that, for each partial quantity of the postinjection injected into the combustion chamber, the reach of the respective fuel jet in the combustion chamber is limited and the reach is less than the distance to a combustion chamber boundary.

Abstract: The present invention relates to novel morpholine-bridged indazole derivatives having the formula which stimulate soluble guanylate cyclase, to a process for the preparation thereof, and to pharmaceutical compositions containing them. These compounds are useful for the treatment of disorders of the central nervous system.

Abstract: The present invention relates to novel 4-amino-substituted pyrimidine derivatives which stimulate soluble guanylate cyclase, to processes for the preparation thereof, and to the use thereof for producing medicaments, in particular medicaments for the treatment of central nervous system diseases.